Cancer News

FDA approves darolutamide for non-metastatic castration-resistant prostate cancer (08/01/2019)

FDA approves darolutamide for non-metastatic castration-resistant prostate cancer On July 30, 2019, the Food and Drug Administration approved darolutamide (NUBEQA, Bayer HealthCare Pharmaceuticals Inc.) for non-metastatic castration-resistant prostate cancer. Approval was based on ARAMIS (NCT02200614), a multicenter, double-blind, placebo-controlled clinical trial in 1,509 patients with non-metastatic castration resistant prostate cancer. Patients were randomized (2:1) to... Continue Reading

New Surgical Technique Shows Potential in Restoring Erectile Function After Radical Prostatectomy (07/09/2019)

Cancer Connect News: According to a report from Australian doctors published in the Journal of European Urology minimally invasive end to end nerve grafting can restore erectile function among men who previously underwent radical prostatectomy for prostate cancer. Every year, nearly 1.3 million men worldwide undergo radical prostatectomy for the treatment of early stage prostate... Continue Reading

Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer (06/03/2019)

After 3 years, 80% of men with metastatic hormone-sensitive prostate cancer who received enzalutamide along with testosterone suppression were alive compared to 72% of men who received standard care. Chicago – Enzalutamide, an oral androgen receptor inhibitor, can improve outcomes for men with metastatic hormone-sensitive prostate cancer (mHSPC), according to a large study presented during... Continue Reading

Zytig Treatment Prolongs Survival in Advanced Prostate Cancer (05/07/2019)

Zytig (Abiraterone acetate) plus prednisone and androgen deprivation therapy (ADT) significantly extends overall survival compared with placebo plus ADT in men with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (CSPC) About Zytig Zytiga is an oral targeted agent that blocks the production of androgens (male hormones such as testosterone) not only by the testes, but... Continue Reading

Darolutamide Delays Prostate Cancer Progression in Men with Resistant Prostate Cancer (03/14/2019)

Results of the phase III ARAMIS clinical trial were published in The New England Journal of Medicine and demonstrated that Darolutamide plus androgen deprivation therapy (ADT) significantly extends metastasis-free survival compared to placebo plus ADT in non-metastatic castration-resistant prostate cancer Darolutamide treated patients survived an average of 40.4 months with evidence of metastases compared to... Continue Reading

Adjuvant Taxotere Doesn’t Improve Outcomes in Early Stage High Risk Prostate Cancer (02/11/2019)

Patients with high-risk, non-metastatic prostate cancer saw no survival advantage and no delay in metastases with the addition of adjuvant docetaxel to androgen deprivation therapy (ADT), according to the results of a pivotal clinical randomized trial published in JAMA Oncology. The clinical trial included 254 men with androgen-dependent, non-metastatic prostate cancer with rising PSA levels.... Continue Reading

Targeted Radiation with 177Lu-PSMA-617 is Promising Treatment for Advanced Prostate Cancer (12/31/2018)

177Lu-PSMA-617 is a member of a new class of drugs that deliver radiation directly to tumor cells to obliterate them. These targeted radiation treatments consist of a radioactive isotope attached to a molecule that specifically targets tumor cells. In this case, the radioactive isotope is 177-lutetium (177Lu), an unstable form of the element lutetium, which …

Continue reading "Targeted Radiation with 177Lu-PSMA-617 is Promising Treatment for Advanced Prostate Cancer"

FDA Approves Xtandi for Treatment of Castration-resistant Prostate Cancer (07/17/2018)

On July 13, 2018, the Food and Drug Administration approved Xtandi (enzalutamide) for patients with castration-resistant prostate cancer (CRPC).  This approval broadens the indicated patient population to include patients with both non-metastatic CRPC (NM-CRPC) and metastatic CRPC. Xtandi was previously approved for the treatment of patients with metastatic CRPC. About Prostate Cancer Prostate cancer is …

Continue reading "FDA Approves Xtandi for Treatment of Castration-resistant Prostate Cancer"

Immediate vs Delayed Androgen Deprivation Therapy in Prostate Cancer (05/01/2018)

CancerConnect News: There is an ongoing discussion about the optimal timing of using androgen deprivation therapy (ADT) in men with prostate cancer who have relapsed based on a rising prostate-specific antigen (PSA) and in men with early stage prostate cancer who are unable to receive more aggressive treatment. Some experts believe that ADT should be …

Continue reading "Immediate vs Delayed Androgen Deprivation Therapy in Prostate Cancer"

Xtandi® A New Standard Treatment for Men with Non-Metastatic Castration-Resistant Prostate Cancer? (02/22/2018)

CancerConnect News:  Results from the Phase 3 PROSPER clinical trial in patients with non-metastatic Castration-Resistant Prostate Cancer (CRPC) were released this week at the 2018 Genitourinary Cancers Symposium in San Francisco and demonstrate that the use of Xtandi® (enzalutamide) plus androgen deprivation therapy (ADT) significantly reduced the risk of developing metastases or death by 71 …

Continue reading "Xtandi® A New Standard Treatment for Men with Non-Metastatic Castration-Resistant Prostate Cancer?"